文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability.

作者信息

Culpepper Larry, Muskin Philip R, Stahl Stephen M

机构信息

Department of Family Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Mass.

Department of Psychiatry, Columbia University Medical Center, New York, NY.

出版信息

Am J Med. 2015 Sep;128(9 Suppl):S1-S15. doi: 10.1016/j.amjmed.2015.07.001.


DOI:10.1016/j.amjmed.2015.07.001
PMID:26337210
Abstract

INTRODUCTION: Major depressive disorder is a complex and frequent psychiatric condition that poses significant challenges to both the patients who experience it and the physicians who treat them. The goal of therapy is for patients to achieve remission, which requires identifying and measuring symptoms at the outset and throughout treatment to document both response and resistance to treatment. A number of validated instruments are available both for diagnosis of and response to treatment. Many factors affect a patient's ability to achieve remission, but although many patients do achieve remission, a significant number continue to have residual symptoms that cause functional impairment. METHODS: Review of the literature for treatment of major depression, including mechanisms of action, individualized treatment optimization, residual symptom reduction, and minimization of side effects. RESULTS: For sustained remission, all symptoms must be treated until they are undetectable. Patients who do not achieve remission after adequate treatment trials should be evaluated for adherence to treatment, as well as comorbid psychiatric and medical disorders. In these cases, consideration should be given to changing therapy by switching, combining, or augmenting initial therapy, as well as referring some patients to a psychiatrist for treatment with specialized modalities. Linking symptoms with malfunctioning brain circuits and neurotransmitters provides a targeted approach for achieving sustained remission. Neurobiology also provides a rational basis for combination therapy in patients with treatment-resistant depression, because it can aid selection of different drugs with different mechanisms of action or of multifunctional/multimodal antidepressant drugs that target more than 1 molecular mechanism. DISCUSSION: Recent advances and better understanding of neurobiology provide a rational basis for individualizing treatment of patients with major depression.

摘要

相似文献

[1]
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability.

Am J Med. 2015-9

[2]
[Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].

Encephale. 2003

[3]
Using antipsychotic agents in older patients.

J Clin Psychiatry. 2004

[4]
Major depressive disorder: remission of associated symptoms.

J Clin Psychiatry. 2006

[5]
Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.

Expert Opin Pharmacother. 2009-12

[6]
Achieving remission and managing relapse in depression.

J Clin Psychiatry. 2003

[7]
[Antidepressive agents in the elderly].

Tijdschr Gerontol Geriatr. 1990-12

[8]
Augmenting antidepressants with folate: a clinical perspective.

J Clin Psychiatry. 2007

[9]
Treating partial responders to antidepressant treatment.

J Clin Psychiatry. 2009-9

[10]
Prevalence and outcome of partial remission in depression.

J Psychiatry Neurosci. 2002-7

引用本文的文献

[1]
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.

Psychopharmacology (Berl). 2025-8-11

[2]
An Adapted Friendship Bench Counseling Intervention (FB) to Improve Mental Health and HIV Care Engagement Outcomes Among People Living with HIV (PWH) Who Inject Drugs in Hanoi, Vietnam: Results from the VITAL Pilot Randomized Controlled Trial.

AIDS Behav. 2025-6

[3]
Treatment-resistant depression: molecular mechanisms and management.

Mol Biomed. 2024-10-17

[4]
Relationship of prefrontal cortex activity with anhedonia and cognitive function in major depressive disorder: an fNIRS study.

Front Psychiatry. 2024-9-19

[5]
Automated mood disorder symptoms monitoring from multivariate time-series sensory data: getting the full picture beyond a single number.

Transl Psychiatry. 2024-3-26

[6]
Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.

BMC Psychiatry. 2023-12-13

[7]
Characteristics of persistent depression in the long-term: Randomized controlled trial and two-year observational study.

Heliyon. 2023-10-13

[8]
Ecosystem health and malfunctions: an organisational perspective.

Biol Philos. 2023

[9]
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.

Psychopharmacology (Berl). 2023-8-22

[10]
The Effects of Adding Art Therapy to Ongoing Antidepressant Treatment in Moderate-to-Severe Major Depressive Disorder: A Randomized Controlled Study.

Int J Environ Res Public Health. 2022-12-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索